#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Diagnostická, prognostická a prediktivní imunohistochemie při maligním melanomu kůže


Autoři: Roncati Luca
Působiště autorů: Department of Diagnostic and Clinical Medicine and of Public Health, Institute of Pathology, University of Modena and Reggio Emilia, Modena, Italy
Vyšlo v časopise: Klin Onkol 2018; 31(2): 152-155
Kategorie: Aktuality v onkologii
doi: https://doi.org/10.14735/amko2018152

Souhrn

Autor deklaruje, že v souvislosti s předmětem studie nemá žádné komerční zájmy.

Redakční rada potvrzuje, že rukopis práce splnil ICMJE kritéria pro publikace zasílané do biomedicínských časopisů.

Obdrženo:
25. 12. 2017

Přijato:
4. 1. 2018


Zdroje

1. Roncati L, Piscioli F, Pusiol T et al. Microinvasive radial growth phase of cutaneous melanoma: a histopathological and immunohistochemical study with diagnostic implications. Acta Dermatovenerol Croat 2017; 25 (1): 39–45.

2. Coons AH, Creech HJ, Jones RN. Immunological properties of an antibody containing a fluorescent group. Proc Soc Exp Biol Med 1941; 47 : 200–202.

3. Roncati L, Manenti A, Sighinolfi P. Immunohistochemi-cal improvement in the analysis of the lymphatic metastases from lung carcinoma. Ann Thorac Surg 2014; 97 (1): 380–381. doi: 10.1016/j.athoracsur.2013.06.072.

4. Marenholz I, Heizmann CW, Fritz G. S100 proteins in mouse and man: from evolution to function and pathology (including an update of the nomenclature). Biochem Biophys Res Commun 2004; 322 (4): 1111–1122. doi: 10.1016/j.bbrc.2004.07.096.

5. Donato R. Intracellular and extracellular roles of S100 proteins. Microsc Res Tech 2003; 60 (6): 540–551. doi: 10.1002/jemt.10296.

6. Nonaka D, Chiriboga L, Rubin BP. Differential expression of S100 protein subtypes in malignant melanoma, and benign and malignant peripheral nerve sheath tumors. J Cutan Pathol 2008; 35 (11): 1014–1019. doi: 10.1111/j.1600-0560.2007.00953.x.

7. Bioley G, Jandus C, Tuyaerts S et al. Melan-A/MART-1-specific CD4 T cells in melanoma patients: identification of new epitopes and ex vivo visualization of specific T cells by MHC class II tetramers. J Immunol 2006; 177 (10): 6769–6779. doi: 10.1111/j.1600-0560.2007.00953.x.

8. Du J, Miller AJ, Widlund HR et al. MLANA/MART1 and SILV/PMEL17/GP100 are transcriptionally regulated by MITF in melanocytes and melanoma. Am J Pathol 2003; 163 (1): 333–343. doi: 10.1016/S0002-9440 (10) 63657-7.

9. Léger S, Balguerie X, Goldenberg A et al. Novel and recurrent non-truncating mutations of the MITF basic domain: genotypic and phenotypic variations in Waardenburg and Tietz syndromes. Eur J Hum Genet 2012; 20 (5): 584–587. doi: 10.1038/ejhg.2011.234.

10. Hershey CL, Fisher DE. Mitf and Tfe3: members of a b-HLH-ZIP transcription factor family essential for osteoclast development and function. Bone 2004; 34 (4): 689–696. doi: 10.1016/j.bone.2003.08.014.

11. Tudrej KB, Czepielewska E, Kozłowska-Wojciechowska M. SOX10-MITF pathway activity in melanoma cells. Arch Med Sci 2017; 13 (6): 1493–1503. doi: 10.5114/aoms. 2016.60655.

12. Wasmeier C, Hume AN, Bolasco G et al. Melanosomes at a glance. J Cell Sci 2008; 121 (24): 3995–3999. doi: 10.1242/jcs.040667.

13. Kapur RP, Bigler SA, Skelly M et al. Anti-melanoma monoclonal antibody HMB45 identifies an oncofetal glycoconjugate associated with immature melanosomes. J Histochem Cytochem 1992; 40 (2): 207–212. doi: 10.1177/40.2.1552165.

14. Clarkson KS, Sturdgess IC, Molyneux AJ. The usefulness of tyrosinase in the immunohistochemical assessment of melanocytic lesions: a comparison of the novel T311 antibody (anti-tyrosinase) with S-100, HMB45, and A103 (anti-melan-A). J Clin Pathol 2001; 54 (3): 196–200.

15. Roncati L, Piscioli F, Pusiol T. The significance of regression in thin melanoma of the skin. Ir J Med Sci 2017; 187 (1): 95–96. doi: 10.1007/s11845-017-1612-1.

16. Roncati L, Vergari B, Del Gaudio A. The ‚all-or-none law‘ applied to the vertical growth phase of cutaneous malignant melanoma. Chonnam Med J 2017; 53 (3): 234–235. doi: 10.4068/cmj.2017.53.3.234.

17. Roncati L, Pusiol T, Piscioli F. Prognostic predictors of thin melanoma in clinico-pathological practice. Acta Dermatovenerol Croat 2017; 25 (2): 159–160.

18. Roncati L, Piscioli F, Pusiol T. Clinical application of the unifying concept of cutaneous melanoma. Chonnam Med J 2017; 53 (1): 78–80. doi: 10.4068/cmj.2017.53.1.78.

19. Piscioli F, Pusiol T, Roncati L. Wisely choosing thin melanomas for sentinel lymph node biopsy. J Am Acad Dermatol 2017; 76 (1): e25. doi: 10.1016/j.jaad.2016.08.069.

20. Roncati L, Piscioli F, Pusiol T. SAMPUS, MELTUMP and THIMUMP –⁠ Diagnostic categories characterized by uncertain biological behavior. Klin Onkol 2017; 30 (3): 221–223. doi: 10.14735/amko2017221.

21. Piscioli F, Pusiol T, Roncati L. Histopathological determination of thin melanomas at risk for metastasis. Melanoma Res 2016; 26 (6): 635. doi: 10.1097/CMR.000 0000000000288.

22. Piscioli F, Pusiol T, Roncati L. Nowadays a histological sub-typing of thin melanoma is demanded for a proper patient management. J Plast Reconstr Aesthet Surg 2016; 69 (11): 1563–1564. doi: 10.1016/j.bjps.2016.08.026.

23. Pusiol T, Piscioli F, Speziali L et al. Clinical features, dermoscopic patterns, and histological diagnostic model for melanocytic tumors of uncertain malignant potential (MELTUMP). Acta Dermatovenerol Croat 2015; 23 (3): 185–194.

24. Piscioli F, Pusiol T, Roncati L. Thin melanoma subtyping fits well with the American Joint Committee on Cancer staging system. Melanoma Res 2016; 26 (6): 636. doi: 10.1097/CMR.0000000000000301.

25. Piscioli F, Pusiol T, Roncati L. Critical points of T1 stage in primary melanoma. Melanoma Res 2017; 27 (4): 399. doi: 10.1097/CMR.0000000000000357.

26. Roncati L, Pusiol T, Piscioli F. Up-to-date proposal for a histologic subcategorization of thin melanomas. Adv Anat Pathol 2017. doi: 10.1097/PAP.0000000000000148.

27. Roncati L, Piscioli F, Pusiol T. The importance of mitotic rate reporting in primary cutaneous melanoma. J Surg Oncol 2017; 116 (7): 958–959. doi: 10.1002/jso.24738.

28. Roncati L, Piscioli F, Pusiol T. Surgical outcomes reflect the histological types of cutaneous malignant melanoma. J Eur Acad Dermatol Venereol 2017; 31 (6): e279–e280. doi: 10.1111/jdv.14023.

29. Roncati L, Piscioli F, Pusiol T. Sentinel lymph node in thin and thick melanoma. Klin Onkol 2016; 29 (5): 393–394.

30. Roncati L, Piscioli F, Pusiol T. Current controversies on sentinel node biopsy in thin and thick cutaneous melanoma. Eur J Surg Oncol 2017; 43 (2): 506–507. doi: 10.1016/j.ejso.2016.09.014.

31. Roncati L, Manenti A, Piscioli F et al. The immune score as a further prognostic indicator in carcinoid tumors. Chest 2017; 151 (5): 1186. doi: 10.1016/j.chest.2016.10. 032.

32. Roncati L, Manenti A, Piscioli F et al. Immunoscoring the lymphocytic infiltration in carcinoid tumours. Histopathology 2017; 70 (7): 1175–1177. doi: 10.1111/his.13168.

33. Roncati L, Manenti A, Farinetti A et al. The association between tumor-infiltrating lymphocytes (TILs) and metastatic course in neuroendocrine neoplasms. Surgery 2016; 160 (6): 1709. doi: 10.1016/j.surg.2015.12.030.

34. Roncati L, Barbolini G, Piacentini F et al. Prognostic factors for breast cancer: an immunomorphological update. Pathol Oncol Res 2016; 22 (3): 449–452. doi: 10.1007/s12253-015-0024-7.

35. Piscioli F, Pusiol T, Roncati L. Diagnostic disputes regarding atypical melanocytic lesions can be solved by using the term MELTUMP. Turk Patoloji Derg 2016; 32 (1): 63–64. doi: 10.5146/tjpath.2015.01330.

36. Piscioli F, Pusiol T, Roncati L. Diagnostic approach to melanocytic lesion of unknown malignant potential. Melanoma Res 2016; 26 (1): 91–92. doi: 10.1097/CMR.000 0000000000215.

37. Roncati L, Barbolini G, Sartori G et al. Loss of CDKN2A promoter methylation coincides with the epigenetic transdifferentiation of uterine myosarcomatous cells. Int J Gynecol Pathol 2016; 35 (4): 309–315. doi: 10.1097/PGP. 0000000000000181.

38. Zhang D, Zhu R, Zhang H et al. MGDB: a comprehensive database of genes involved in melanoma. Database (Oxford) 2015; 2015: pii: bav097. doi: 10.1093/database/bav097.

39. Lovly CM, Dahlman KB, Fohn LE et al. Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials. PLoS One 2012; 7 (4): e35309. doi: 10.1371/journal.pone.0035309.

40. Wong DJ, Ribas A. Targeted therapy for melanoma. Cancer Treat Res 2016; 167 : 251–262. doi: 10.1007/978-3-319-22539-5_10.

41. Lulli D, Carbone ML, Pastore S. The MEK inhibitors trametinib and cobimetinib induce a type I interferon response in human keratinocytes. Int J Mol Sci 2017; 18 (10). doi: 10.3390/ijms18102227.

42. Queirolo P, Spagnolo F. Binimetinib for the treatment of NRAS-mutant melanoma. Expert Rev Anticancer Ther 2017; 17 (11): 985–990. doi: 10.1080/1473 7140.2017.1374177.

43. Costa R, Costa RB, Talamantes SM et al. Meta-analysis of selected toxicity endpoints of CDK4/6 inhibitors: palbociclib and ribociclib. Breast 2017; 35 : 1–7. doi: 10.1016/j.breast.2017.05.016.

44. Roncati L, Barbolini G, Gatti AM et al. The uncontrolled sialylation is related to chemoresistant metastatic breast cancer. Pathol Oncol Res 2016; 22 (4): 869–873. doi: 10.1007/s12253-016-0057-6.

45. Murer C, Kränzlin-Stieger P, French LE et al Successful treatment with imatinib after nilotinib and ipilimumab in a c-kit-mutated advanced melanoma patient: a case report. Melanoma Res 2017; 27 (4): 396–398. doi: 10.1097/ CMR.0000000000000358.

46. Najem A, Krayem M, Perdrix A et al. New drug combination strategies in melanoma: current status and future directions. Anticancer Res 2017; 37 (11): 5941–5953. doi: 10.21873/anticanres.12041.

47. Karlsson AK, Saleh SN. Checkpoint inhibitors for malignant melanoma: a systematic review and meta-analysis. Clin Cosmet Investig Dermatol 2017; 10 : 325–339. doi: 10.2147/CCID.S120877.

48. Walunas TL, Lenschow DJ, Bakker CY et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1994; 1 (5): 405–413.

49. Letendre P, Monga V, Milhem M et al. Ipilimumab: from preclinical development to future clinical perspectives in melanoma. Future Oncol 2017; 13 (7): 625–636. doi: 10.2217/fon-2016-0385.

50. Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. Immunol Rev 2010; 236 : 219–242. doi: 10.1111/j.1600-065X.2010.00923.x.

51. Wang X, Teng F, Kong L et al. PD-L1 expression in human cancers and its association with clinical outcomes. Onco Targets Ther 2016; 9 : 5023–5039. doi: 10.2147/OTT.S105862.

52. Prasad V, Kaestner V. Nivolumab and pembrolizumab: monoclonal antibodies against programmed cell death-1 (PD-1) that are interchangeable. Semin Oncol 2017; 44 (2): 132–135. doi: 10.1053/j.seminoncol.2017. 06.007.

53. Syn NL, Teng MWL, Mok TSK et al. De-novo and acquired resistance to immune checkpoint targeting. Lancet Oncol 2017; 18 (12): e731–e741. doi: 10.1016/ S1470-2045 (17) 30607-1.

54. Kubeček O, Kopecký J. Microsatellite instability in melanoma: a comprehensive review. Melanoma Res 2016; 26 (6): 545–550. doi: 10.1097/CMR.0000000000000298.

55. Kim ST, Klempner SJ, Park SH et al. Correlating programmed death ligand 1 (PD-L1) expression, mismatch repair deficiency, and outcomes across tumor types: implications for immunotherapy. Oncotarget 2017; 8 (44): 77415–77423. doi: 10.18632/oncotarget.20 492.

56. Kubecek O, Trojanova P, Molnarova V et al. Microsatellite instability as a predictive factor for immunotherapy in malignant melanoma. Med Hypotheses 2016; 93 : 74–76. doi: 10.1016/j.mehy.2016.05.023.

57. Roncati L, Manenti A, Pusiol T et al. Testosterone aromatization to estradiol in course of ovarian functioning Brenner tumor associated with endometrial carcinoma and endometriosis (Roncati-Manenti triad). Int J Gynecol Cancer 2016; 26 (8): 1461–1464. doi: 10.1097/IGC.0000000000000779.

Štítky
Dětská onkologie Chirurgie všeobecná Onkologie

Článek vyšel v časopise

Klinická onkologie

Číslo 2

2018 Číslo 2
Nejčtenější tento týden
Nejčtenější v tomto čísle
Kurzy

Zvyšte si kvalifikaci online z pohodlí domova

Mepolizumab v reálné klinické praxi kurz
Mepolizumab v reálné klinické praxi
nový kurz
Autoři: MUDr. Eva Voláková, Ph.D.

BONE ACADEMY 2025
Autoři: prof. MUDr. Pavel Horák, CSc., doc. MUDr. Ludmila Brunerová, Ph.D., doc. MUDr. Václav Vyskočil, Ph.D., prim. MUDr. Richard Pikner, Ph.D., MUDr. Olga Růžičková, MUDr. Jan Rosa, prof. MUDr. Vladimír Palička, CSc., Dr.h.c.

Cesta pacienta nejen s SMA do nervosvalového centra
Autoři: MUDr. Jana Junkerová, MUDr. Lenka Juříková

Svět praktické medicíny 2/2025 (znalostní test z časopisu)

Eozinofilní zánět a remodelace
Autoři: MUDr. Lucie Heribanová

Všechny kurzy
Kurzy Podcasty Doporučená témata Časopisy
Přihlášení
Zapomenuté heslo

Zadejte e-mailovou adresu, se kterou jste vytvářel(a) účet, budou Vám na ni zaslány informace k nastavení nového hesla.

Přihlášení

Nemáte účet?  Registrujte se

#ADS_BOTTOM_SCRIPTS#